BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

Key Points

• BioMarin issued FY 2026 guidance below Wall Street expectations, forecasting EPS of $2.80–$3.10 versus a $3.32 consensus and revenue of $3.8–$3.9 billion versus $3.9 billion expected.
• Third-quarter results were strong: revenue rose 32% year over year to $1.025 billion, while adjusted EPS of $0.23 exceeded expectations for a loss of $0.08. Growth was led by metabolic-condition revenue, which increased 44%.
• Shares fell 1.8% following the guidance update, although analysts maintained a “Moderate Buy” consensus with an average price target of $88.30, well above the reported opening price of $57.44.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.100 for the period, compared to the consensus estimate of 3.320. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

BioMarin Pharmaceutical Stock Down 1.8%

BMRN opened at $57.44 on Tuesday. The business has a 50 day simple moving average of $60.43 and a 200-day simple moving average of $58.46. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $70.98. The stock has a market capitalization of $11.12 billion, a P/E ratio of 33.33, a P/E/G ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.31. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the prior year, the business posted $0.12 earnings per share. BioMarin Pharmaceutical's revenue was up 32.0% compared to the same quarter last year. On average, equities analysts anticipate that BioMarin Pharmaceutical will post 2.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BMRN. Royal Bank Of Canada reduced their price objective on BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a report on Tuesday, July 7th. Citigroup upped their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a "buy" rating in a report on Thursday, July 16th. UBS Group started coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, October 15th. They issued a "buy" rating and a $88.00 price target on the stock. HC Wainwright reissued a "neutral" rating and set a $60.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Finally, JPMorgan Chase & Co. lifted their price objective on BioMarin Pharmaceutical from $86.00 to $87.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 20th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $88.30.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted earnings of $0.23 per share significantly exceeded consensus expectations for a loss. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry-disease asset to its clinical portfolio, broadening its rare-disease pipeline. Analysts described the recent setback as timing-related and maintained a constructive long-term view; Citi reiterated a Buy rating with projected upside. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Positive Sentiment: BioMarin said VOXZOGO for hypochondroplasia has a May 30, 2027 PDUFA action date, providing a potential future growth catalyst in skeletal conditions. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Several valuation analyses suggested BMRN may be undervalued—one estimated approximately 21% potential upside—although those assessments depend on the company restoring execution and meeting longer-term growth expectations. BioMarin Pharmaceutical Could Be 21% Undervalued
• Negative Sentiment: BioMarin lowered its 2026 guidance, citing uncertainty over order timing and the impact of two acquired in-process research and development charges. Although the quarterly revenue result was on target, the reduced full-year sales outlook is the main reason investors remain cautious. BioMarin Q3 Earnings and Lowered 2026 Guidance

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.